This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Herbalife Second Quarter Earnings: Live Blog

Live Blog Herbalife Second Quarter Earnings: Live Blog
 

NEW YORK (TheStreet) - Herbalife (HLF - Get Report), on Monday evening, reported disappointing second quarter earnings that were below Wall Street consensus. The multi-level supplements seller also lowered its revenue guidance for the third quarter and full-year, causing shares to tumble over 10%.

Los Angeles-based Herbalife has been waging a multi-year battle against hedge fund billionaire William Ackman of Pershing Square Capital Management, who bet $1 billion against the company's shares and called it a pyramid scheme. Herbalife has strongly denied Ackman's claims and spent tens of millions of dollars on advisors and public relations campaigns to rebut the hedge funder's assertions.

Last Tuesday, Ackman caused quite the roller-coaster in Herbalife shares when he took to CNBC and Bloomberg to pitch a three-hour presentation that would show the company to be a fraud. On Wednesday, his presentation disclosed new information on the way Herbalife's network of Nutrition Clubs work. He alleged that most of Herbalife's apparent Nutrition Club customers are actually part of the company's recruitment chain. Herbalife, however, stood by its business and said Ackman had over-promised and under-delivered with his presentation.

Must Read: Ackman and Herbalife -- The Day After 

While Ackman's presentation was revealing, it did not contain the smoking gun he'd promised. Herbalife shares surged 26%, their most on record. Shares are now giving back gains in the wake of Herbalife's disappointing earnings and guidance. Those who remain believers in Herbalife are likely going to tune into the company's earnings call to get a better understanding of why earnings fell short and guidance is falling.

On Monday, Herbalife left language about regulatory probes into its business unchanged:

Given the nature of recent allegations made by certain short sellers and related market events, the Company has received and believes it may receive additional state and federal governmental and similar inquiries (such as the previously disclosed inquiries from the FTC and SEC). To the extent any of these inquiries are or become material they will be disclosed individually. Consistent with its policies, the Company is and will fully cooperate with any inquiries and looks forward to resolving them in a timely manner.

Herbalife did disclose that regulatory probes are costing its business far more than in previous quarters. Expenses tied to the FTC's probe more than quadrupled in the second quarter to $5.1 million.

The company reported revenue of $1.3 billion and adjusted earnings per share of $1.55, both slightly missing estimates compiled by Bloomberg. The company also generated cash flow of $156.9 million and repurchased $581 million of stock, or 9.8 million shares.

For the third quarter, Herbalife now expects between 9% and 11% net sales growth and diluted earnings per share of between $1.49 and $1.53 a share. For the full-year, the company now expects between 8.5%-to-10.5% net sales growth and diluted EPS of up to $6.32 a share. Those estimates reflect a fall in Herbalife's guidance on revenue, but a rise in EPS.

TheStreet will be live-blogging Herbalife's conference call on Tuesday, starting at 10:45 a.m..

Must Read: Ackman's 2014 Gains May Give Time to Herbalife Short

Must Read: Herbalife and Ackman Spend in Washington

-- Written by Antoine Gara in New York

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
HLF $42.07 1.08%
AAPL $128.70 -0.19%
FB $78.81 -0.23%
GOOG $540.78 0.54%
TSLA $230.51 1.98%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs